Detecting and genotyping high-risk human papillomavirus among male patients during 2015–2023 in Beijing, China
ABSTRACTFew studies focused on human papillomavirus (HPV) in male patients. This study aimed to explore the detection rate and genotyping of HPV among male patients in Beijing to provide a reference for formulating prevention strategies for HPV infection. The cross-sectional study was conducted in B...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Emerging Microbes and Infections |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/22221751.2024.2313848 |
| _version_ | 1797315606386573312 |
|---|---|
| author | Shuai Wang Qin-Yi Ma Juan Du Ting-Ting Wei Wan-Xue Zhang Peng Wang Yiguo Zhou Ming Wei Li Gu Fuqiang Cui Qing-Bin Lu |
| author_facet | Shuai Wang Qin-Yi Ma Juan Du Ting-Ting Wei Wan-Xue Zhang Peng Wang Yiguo Zhou Ming Wei Li Gu Fuqiang Cui Qing-Bin Lu |
| author_sort | Shuai Wang |
| collection | DOAJ |
| description | ABSTRACTFew studies focused on human papillomavirus (HPV) in male patients. This study aimed to explore the detection rate and genotyping of HPV among male patients in Beijing to provide a reference for formulating prevention strategies for HPV infection. The cross-sectional study was conducted in Beijing Chaoyang Hospital from November 2015 to March 2023. It covered male patients from the urology and dermatology departments. Fifteen high-risk HPV genotypes were detected by the multiplex real-time polymerase chain reaction method. The overall detection rate of HPV was 25.19% (1288/5114, 95% confidence interval [CI] 24.00%−26.38%), of which the single infection rate was 16.99% (869/5114, 95% CI 15.97%−18.05%) and the co-infection rate was 8.19% (419/5114, 95% CI 7.46%−8.98%). The detection rate of HPV was 40.77% (521/1278), 35.58% (58/163), 32.69% (101/309), 31.91% (60/188), 12.63% (299/2367), and 32.35% (131/405) among male patients with balanitis, warts, rash, urethritis, prostatitis, and other urinary inflammation, respectively (P < 0.001). The top five HPV genotypes were HPV-52, HPV-58, HPV-16, HPV-51, and HPV-66. After the first positive HPV test, the proportion of male patients who turned negative was 22.47% within 3 months, 26.40% within 3−6 months, 24.72% within 6−12 months, 17.98% within 12−24 months, and 8.43% more than 24 months. The detection rate of HPV was high among male patients from the urology and dermatology departments in Beijing, which should be considered to develop HPV vaccines with better prevention effects. |
| first_indexed | 2024-03-08T03:06:10Z |
| format | Article |
| id | doaj.art-a30fb6a75c0c4df9af6cf471bfa7c0ea |
| institution | Directory Open Access Journal |
| issn | 2222-1751 |
| language | English |
| last_indexed | 2024-03-08T03:06:10Z |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Emerging Microbes and Infections |
| spelling | doaj.art-a30fb6a75c0c4df9af6cf471bfa7c0ea2024-02-13T09:48:50ZengTaylor & Francis GroupEmerging Microbes and Infections2222-17512024-12-0113110.1080/22221751.2024.2313848Detecting and genotyping high-risk human papillomavirus among male patients during 2015–2023 in Beijing, ChinaShuai Wang0Qin-Yi Ma1Juan Du2Ting-Ting Wei3Wan-Xue Zhang4Peng Wang5Yiguo Zhou6Ming Wei7Li Gu8Fuqiang Cui9Qing-Bin Lu10Department of Infectious Diseases and Clinical Microbiology, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, Beijing, People’s Republic of ChinaDepartment of Laboratorial of Science and Technology & Vaccine Research Center, School of Public Health, Peking University, Beijing, People’s Republic of ChinaDepartment of Laboratorial of Science and Technology & Vaccine Research Center, School of Public Health, Peking University, Beijing, People’s Republic of ChinaDepartment of Laboratorial of Science and Technology & Vaccine Research Center, School of Public Health, Peking University, Beijing, People’s Republic of ChinaDepartment of Laboratorial of Science and Technology & Vaccine Research Center, School of Public Health, Peking University, Beijing, People’s Republic of ChinaDepartment of Infectious Diseases and Clinical Microbiology, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, Beijing, People’s Republic of ChinaDepartment of Laboratorial of Science and Technology & Vaccine Research Center, School of Public Health, Peking University, Beijing, People’s Republic of ChinaDepartment of Infectious Diseases and Clinical Microbiology, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, Beijing, People’s Republic of ChinaDepartment of Infectious Diseases and Clinical Microbiology, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, Beijing, People’s Republic of ChinaDepartment of Laboratorial of Science and Technology & Vaccine Research Center, School of Public Health, Peking University, Beijing, People’s Republic of ChinaDepartment of Laboratorial of Science and Technology & Vaccine Research Center, School of Public Health, Peking University, Beijing, People’s Republic of ChinaABSTRACTFew studies focused on human papillomavirus (HPV) in male patients. This study aimed to explore the detection rate and genotyping of HPV among male patients in Beijing to provide a reference for formulating prevention strategies for HPV infection. The cross-sectional study was conducted in Beijing Chaoyang Hospital from November 2015 to March 2023. It covered male patients from the urology and dermatology departments. Fifteen high-risk HPV genotypes were detected by the multiplex real-time polymerase chain reaction method. The overall detection rate of HPV was 25.19% (1288/5114, 95% confidence interval [CI] 24.00%−26.38%), of which the single infection rate was 16.99% (869/5114, 95% CI 15.97%−18.05%) and the co-infection rate was 8.19% (419/5114, 95% CI 7.46%−8.98%). The detection rate of HPV was 40.77% (521/1278), 35.58% (58/163), 32.69% (101/309), 31.91% (60/188), 12.63% (299/2367), and 32.35% (131/405) among male patients with balanitis, warts, rash, urethritis, prostatitis, and other urinary inflammation, respectively (P < 0.001). The top five HPV genotypes were HPV-52, HPV-58, HPV-16, HPV-51, and HPV-66. After the first positive HPV test, the proportion of male patients who turned negative was 22.47% within 3 months, 26.40% within 3−6 months, 24.72% within 6−12 months, 17.98% within 12−24 months, and 8.43% more than 24 months. The detection rate of HPV was high among male patients from the urology and dermatology departments in Beijing, which should be considered to develop HPV vaccines with better prevention effects.https://www.tandfonline.com/doi/10.1080/22221751.2024.2313848Human papillomavirusmalegenotypeurologyChina |
| spellingShingle | Shuai Wang Qin-Yi Ma Juan Du Ting-Ting Wei Wan-Xue Zhang Peng Wang Yiguo Zhou Ming Wei Li Gu Fuqiang Cui Qing-Bin Lu Detecting and genotyping high-risk human papillomavirus among male patients during 2015–2023 in Beijing, China Emerging Microbes and Infections Human papillomavirus male genotype urology China |
| title | Detecting and genotyping high-risk human papillomavirus among male patients during 2015–2023 in Beijing, China |
| title_full | Detecting and genotyping high-risk human papillomavirus among male patients during 2015–2023 in Beijing, China |
| title_fullStr | Detecting and genotyping high-risk human papillomavirus among male patients during 2015–2023 in Beijing, China |
| title_full_unstemmed | Detecting and genotyping high-risk human papillomavirus among male patients during 2015–2023 in Beijing, China |
| title_short | Detecting and genotyping high-risk human papillomavirus among male patients during 2015–2023 in Beijing, China |
| title_sort | detecting and genotyping high risk human papillomavirus among male patients during 2015 2023 in beijing china |
| topic | Human papillomavirus male genotype urology China |
| url | https://www.tandfonline.com/doi/10.1080/22221751.2024.2313848 |
| work_keys_str_mv | AT shuaiwang detectingandgenotypinghighriskhumanpapillomavirusamongmalepatientsduring20152023inbeijingchina AT qinyima detectingandgenotypinghighriskhumanpapillomavirusamongmalepatientsduring20152023inbeijingchina AT juandu detectingandgenotypinghighriskhumanpapillomavirusamongmalepatientsduring20152023inbeijingchina AT tingtingwei detectingandgenotypinghighriskhumanpapillomavirusamongmalepatientsduring20152023inbeijingchina AT wanxuezhang detectingandgenotypinghighriskhumanpapillomavirusamongmalepatientsduring20152023inbeijingchina AT pengwang detectingandgenotypinghighriskhumanpapillomavirusamongmalepatientsduring20152023inbeijingchina AT yiguozhou detectingandgenotypinghighriskhumanpapillomavirusamongmalepatientsduring20152023inbeijingchina AT mingwei detectingandgenotypinghighriskhumanpapillomavirusamongmalepatientsduring20152023inbeijingchina AT ligu detectingandgenotypinghighriskhumanpapillomavirusamongmalepatientsduring20152023inbeijingchina AT fuqiangcui detectingandgenotypinghighriskhumanpapillomavirusamongmalepatientsduring20152023inbeijingchina AT qingbinlu detectingandgenotypinghighriskhumanpapillomavirusamongmalepatientsduring20152023inbeijingchina |